£73 million

Capital Investment


DUB targets explored


In the DUB field

Commercializing expert research into

Dubs and Ubiquitin pathway

Mission Therapeutics’ strategy is to create value by advancing its pipeline programs through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Selected programmes may be advanced in partnership with other pharmaceutical companies.

Mission Therapeutics © website by Instinctif Partners